treatment with aluminum hydroxide ( fig. 2) , and although plasma aluminum after desferrioxamine (40 mg/kg intravenously) was also higher, the apparent difference was not statistically significant (table 1) . Side effects were minor with both treatments, pruritis and occasional worsening of bone pain (during periods of poor phosphate control) and minor bowel disturbance (constipation with aluminum hydroxide, mild diarrhea in 1 patient with calcium alginate). Five patients preferred to take aluminum hydroxide, 5 calcium alginate and 2 had no preference. Although this study confirms previous reports [2, 3] of the effectiveness of calcium alginate as a single agent in some hemodialysis patients, adequate phosphate control was achieved in 60% of patients only after another phosphate binder was added. However, an extra phosphate binder was also needed in 30% of patients while on aluminum hydroxide, even though the maximum dose of aluminum hydroxide was more than 2 times that currently recommended [5] . As might be expected, evidence of aluminum accumulation improved during treatment with calcium alginate. The previous claims that hypercalcemia is rare with calcium alginate [2, 3] are not substantiated as the incidence of hypercalcemia was similar to that reported with other calcium-containing phosphate binders in which the dose of elemental calcium was higher [6, 7] . Fig. 1 . Serum phosphate during treatment with aluminum hydroxide (O) or calcium alginate (D). *p < 0.05; **p < 0.01. To convert to mg/dl, multiply by 3.1. § 5 E 3 Values are mean ± SEM. Normal values: calcium 2.13-2.63 mmol/l, magnesium 0.65-1.05 mmol/l, alkaline phosphatase 30-115 U/l, parathyroid hormone < 0.4 µg/ml. There were no statistically significant differences between A and C at either 3 or 6 months. Conversion: for calcium in mg/dl multiply by 4; for magnesium in mg/dl multiply by 2.4. -1 -2 3 Months Fig. 2 . Plasma aluminum during treatment with aluminum hydroxide (O) and calcium alginate (¤). *p < 0.05; **p = 0.01.
